- Poster presentation
- Open Access
A novel rabbit monoclonal antibody platform to dissect the diverse repertoire of antibody epitopes for HIV-1 Env immunogen design
© Chen et al; licensee BioMed Central Ltd. 2012
- Published: 13 September 2012
- Boost Vaccination
- Human mAbs
- Vaccination Regimen
- Rabbit mAbs
- Diverse Repertoire
The majority of available monoclonal antibodies (mAbs) in the current HIV vaccine field are generated from HIV-1 infected people. In contrast, preclinical immunogenicity studies have mainly focused on polyclonal antibody responses in experimental animals. Although rabbits have been widely used for antibody studies, there has been no report of using rabbit mAbs to dissect the specificity of antibody responses for AIDS vaccine development.
Here we report the production of a panel of 12 mAbs from one NZW rabbit that was immunized with a HIV-1 JR-FL gp120 DNA prime and protein boost vaccination regimen.
These rabbit mAbs recognized a diverse repertoire of epitopes. Besides the traditional highly immunogenic V3 region, these mAbs recognized several previously underappreciated epitopes in the C1, C4, and C5 regions. Nine mAbs showed cross-reactivity against gp120s of clades other than clade B. At least three mAbs showed neutralizing activities with various breadth and potency. Increased somatic mutation percentage and long CDR3 were observed with some of the rabbit mAbs. More interestingly, phylogenic tree analysis showed that the heavy chain of mAbs recognizing the same region on gp120 were segregated into an independent subtree, implicating that these mAbs may derive from the same B cell precursor. Crystal structures of several rabbit mAbs suggested that these rabbit mAbs generated from vaccines mimic the binding modes of well-characterized human mAbs isolated from infected individuals.
Therefore, isolation of mAbs from vaccinated rabbits provides us an opportunity to study the evolution and affinity maturation of HIV-1 Env-specific mAbs elicited by candidate AIDS vaccines.
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.